|
Name |
Austradixanthone
|
Molecular Formula | C30H22O13 | |
IUPAC Name* |
5-[3,8-dihydroxy-6-(hydroxymethyl)-1-methyl-9-oxoxanthen-4-yl]oxy-2,3,4,6-tetrahydroxy-1-methoxy-8-methylxanthen-9-one
|
|
SMILES |
CC1=CC(=C(C2=C1C(=O)C3=C(C=C(C=C3O2)CO)O)OC4=C(C=C(C5=C4OC6=C(C5=O)C(=C(C(=C6O)O)O)OC)C)O)O
|
|
InChI |
InChI=1S/C30H22O13/c1-9-4-13(33)25(29-16(9)20(35)18-12(32)6-11(8-31)7-15(18)41-29)42-26-14(34)5-10(2)17-21(36)19-27(40-3)23(38)22(37)24(39)28(19)43-30(17)26/h4-7,31-34,37-39H,8H2,1-3H3
|
|
InChIKey |
BPTCPKOWYXWSTG-UHFFFAOYSA-N
|
|
Synonyms |
Austradixanthone; CHEMBL4522416; J3.547.658J; 4-[3,8-Dihydroxy-6-(hydroxymethyl)-1-methyl-9-oxo-9H-xanthene-4-yloxy]-3,5,6,7-tetrahydroxy-8-methoxy-1-methyl-9H-xanthene-9-one
|
|
CAS | NA | |
PubChem CID | 132519905 | |
ChEMBL ID | CHEMBL4522416 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 590.5 | ALogp: | 3.8 |
HBD: | 7 | HBA: | 13 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 213.0 | Aromatic Rings: | 6 |
Heavy Atoms: | 43 | QED Weighted: | 0.108 |
Caco-2 Permeability: | -5.453 | MDCK Permeability: | 0.00000957 |
Pgp-inhibitor: | 0.828 | Pgp-substrate: | 0.077 |
Human Intestinal Absorption (HIA): | 0.889 | 20% Bioavailability (F20%): | 0.004 |
30% Bioavailability (F30%): | 0.046 |
Blood-Brain-Barrier Penetration (BBB): | 0.001 | Plasma Protein Binding (PPB): | 85.53% |
Volume Distribution (VD): | 0.465 | Fu: | 41.57% |
CYP1A2-inhibitor: | 0.205 | CYP1A2-substrate: | 0.567 |
CYP2C19-inhibitor: | 0.023 | CYP2C19-substrate: | 0.046 |
CYP2C9-inhibitor: | 0.576 | CYP2C9-substrate: | 0.186 |
CYP2D6-inhibitor: | 0 | CYP2D6-substrate: | 0.134 |
CYP3A4-inhibitor: | 0.028 | CYP3A4-substrate: | 0.047 |
Clearance (CL): | 1.843 | Half-life (T1/2): | 0.885 |
hERG Blockers: | 0.002 | Human Hepatotoxicity (H-HT): | 0.035 |
Drug-inuced Liver Injury (DILI): | 0.991 | AMES Toxicity: | 0.202 |
Rat Oral Acute Toxicity: | 0.475 | Maximum Recommended Daily Dose: | 0.905 |
Skin Sensitization: | 0.92 | Carcinogencity: | 0.025 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.896 |
Respiratory Toxicity: | 0.021 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004390 | 0.436 | D0K8KX | 0.301 | ||||
ENC005645 | 0.435 | D06GCK | 0.274 | ||||
ENC002867 | 0.410 | D04AIT | 0.259 | ||||
ENC005647 | 0.403 | D0G4KG | 0.232 | ||||
ENC005112 | 0.399 | D0AZ8C | 0.222 | ||||
ENC002018 | 0.390 | D0FX2Q | 0.220 | ||||
ENC000912 | 0.386 | D03RTK | 0.213 | ||||
ENC000922 | 0.386 | D0TC7C | 0.208 | ||||
ENC003507 | 0.386 | D0WY9N | 0.206 | ||||
ENC001765 | 0.382 | D0FA2O | 0.206 |